Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program).
Giuseppe LiscoAnna De TullioVincenzo De GeronimoVito Angelo GiagulliEdoardo GuastamacchiaGiuseppina PiazzollaOlga Eugenia DisoteoTriggiani VincenzoPublished in: Biomedicines (2024)
Insulin Icodec is substantially non-inferior to once-daily insulin analogs in T2D, either insulin-naïve or insulin-treated. However, Icodec works slightly better than competitors when used in a basal-only rather than basal-bolus regimen. Weight gain and hypoglycemic risk are substantially low but not negligible. Patients' education, adequate lifestyle and pharmacological interventions, and appropriate therapy adjustments are essential to minimize risks. This systematic review is registered as PROSPERO CRD42024568680.
Keyphrases
- type diabetes
- glycemic control
- weight gain
- systematic review
- physical activity
- healthcare
- body mass index
- cardiovascular disease
- weight loss
- metabolic syndrome
- ejection fraction
- birth weight
- stem cells
- insulin resistance
- prognostic factors
- climate change
- skeletal muscle
- human health
- molecular dynamics simulations
- smoking cessation